David S. Moore, chief business officer at Ocera Therapeutics, is leaving the company to pursue other opportunities. Mr. Moore was a member of the management team at Tranzyme and continued his employment with Ocera following the merger of the companies in July 2013.   In addition, as part of the transition of Ocera’s corporate headquarters to Palo Alto, CA, Rhonda L. Stanley, controller and principal accounting officer will be leaving the company. Jeryl L. Hilleman, Ocera’s chief fina...